Submitted by endpointsnews6292 in health
Pfizer said it expects fewer people will be needed to complete its Phase III trial of Valneva’s Lyme disease vaccine candidate than originally thought. The so-called VALOR study will enroll about 9,000 people aged five or older to gather efficacy, a Pfizer sp…